Graves Ophthalmopathy Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Graves Ophthalmopathy market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, and others.

[Nevada, United States] - DelveInsight's "Graves Ophthalmopathy Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Graves Ophthalmopathy, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Graves Ophthalmopathy Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Graves Ophthalmopathy Market Report:
• The Graves Ophthalmopathy market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Amgen announced a Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease
• In October, 2024: argenx announced a Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Thyroid Eye Disease
• In October, 2024: Hoffmann-La Roche announced a Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Moderate-to-Severe Thyroid Eye Disease
• In October, 2024: Viridian Therapeutics, Inc. announced a REVEAL-2 - a Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)
• In 2023, the total Graves' Ophthalmopathy market size was around USD 2,600 million, which is expected to increase by 2034 during the study period (2020-2034) in the 7MM.
• With estimated 1 million patients affected in the US, thyroid eye disease is a burden some disorder which become sight threatening in upto 5% of the cases
• As per data by NICE (2019), autoimmune hyperthyroidism (GD) is the most common form and accounts for 60-80% of cases of hyperthyroidism.
• Key Graves Ophthalmopathy Companies are as follows: Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, and others.
• Key Graves Ophthalmopathy Therapies are as follow: TEPEZZA (teprotumumab), Batoclimab (IMVT 1401), VRDN-001, VRDN-003, Batoclimab, Teprotumumab, Efgartigimod, Satralizumab, CFZ533, linsitinib, LASN01
• Launching multiple stage Graves Ophthalmopathy pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Graves Ophthalmopathy market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Graves Ophthalmopathy Overview:
Graves' ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy (TAO) and thyroid eye disease (TED), is the most frequent extrathyroidal manifestation of Graves' disease (GD).
It is an autoimmune disease in which the production of autoantibodies leads to inflammatory changes in the orbit. The autoantibodies presumably target a protein shared by both the orbit and the thyroid.

Graves Ophthalmopathy Epidemiology Segmentation:
The Graves Ophthalmopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Graves Ophthalmopathy Prevalent Cases
• Graves Ophthalmopathy Diagnosed Prevalent Cases
• Graves Ophthalmopathy Acute Diagnosed Prevalent Cases
• Graves Ophthalmopathy Moderate-to-severe Drug-treated Cases

For more information about Graves Ophthalmopathy companies working in the treatment market, visit https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Graves Ophthalmopathy Market Insights
Graves' Ophthalmopathy (GO), also known as Thyroid Eye Disease (TED), is an autoimmune inflammatory disorder that primarily affects the tissues around the eyes. It is commonly associated with Graves' disease, a form of hyperthyroidism. The condition can lead to significant morbidity, including proptosis (bulging eyes), diplopia (double vision), and in severe cases, vision loss. The growing understanding of the pathophysiology of GO and the introduction of novel therapies have shaped the current market landscape, but challenges remain in terms of diagnosis, treatment accessibility, and drug uptake.

Graves Ophthalmopathy Drugs Uptake
• Tepezza is the first FDA-approved treatment for thyroid eye disease and has significantly impacted the market since its approval in 2020. It has become the go-to treatment for moderate to severe Graves' ophthalmopathy in the US, leading to strong market uptake.
• Intravenous glucocorticoids, like methylprednisolone, continue to be a primary treatment for moderate to severe cases of Graves' ophthalmopathy, especially in regions where access to biologics is limited.
• Rituximab, a B-cell depleting agent, has shown promise in treating the inflammatory aspects of the disease, and off-label use is increasing in Europe and North America. Ongoing clinical trials may further support its approval for this indication.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Graves Ophthalmopathy Therapies and Key Companies:
• TEPEZZA (teprotumumab): Horizon Therapeutics/ Amgen
• Batoclimab (IMVT 1401): Immunovant Sciences
• VRDN-001: Viridian Therapeutics
• VRDN-003: Viridian Therapeutics, Inc.
• Batoclimab: Immunovant Sciences GmbH
• Teprotumumab: Amgen
• Efgartigimod: argenx
• Satralizumab: Hoffmann-La Roche
• CFZ533: Novartis
• linsitinib: Sling Therapeutics, Inc.
• LASN01: Lassen Therapeutics 1 PTY LTD

Graves Ophthalmopathy Epidemiology:
The global prevalence of Graves' disease is estimated at 2-3% of the general population, and among these patients, around 25-30% develop moderate to severe ophthalmopathy requiring medical intervention. The incidence of clinically significant Graves' ophthalmopathy is around 16 cases per 100,000 women and 3 cases per 100,000 men per year.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Graves Ophthalmopathy Market Drivers:
• Increased Prevalence of Graves' Disease
• Breakthrough Therapies
• Growing Awareness and Early Diagnosis
• Smoking Cessation and Risk Management

Graves Ophthalmopathy Market Barriers:
• High Cost of Novel Therapies
• Lack of Awareness in Developing Regions
• Adverse Effects of Current Treatments
• Resistance to New Therapies

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Graves Ophthalmopathy Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Graves Ophthalmopathy Companies: Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, and others.
• Key Graves Ophthalmopathy Therapies: TEPEZZA (teprotumumab), Batoclimab (IMVT 1401), VRDN-001, VRDN-003, Batoclimab, Teprotumumab, Efgartigimod, Satralizumab, CFZ533, linsitinib, LASN01
• Graves Ophthalmopathy Therapeutic Assessment: Current marketed and emerging therapies
• Graves Ophthalmopathy Market Dynamics: Graves Ophthalmopathy Market drivers and Graves Ophthalmopathy barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graves Ophthalmopathy Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Graves Ophthalmopathy market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/graves-ophthalmopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Graves' Ophthalmopathy Market Overview at a Glance
4 Executive Summary of Graves' Ophthalmopathy
5 Graves' ophthalmopathy Epidemiology and Market Methodology
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Patient Journey
9 Key Endpoints in Graves' Ophthalmopathy Clinical Trials
10 Marketed Therapies
11 Emerging Therapies
12 Graves' Ophthalmopathy: The 7MM Analysis
13 Graves' Ophthalmopathy Market Access and Reimbursement
15 Graves' Ophthalmopathy SWOT Analysis
16 Graves' Ophthalmopathy Unmet Needs
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.